Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:32 PM
Ignite Modification Date:
2025-12-24 @ 5:32 PM
NCT ID:
NCT00021268
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of metastatic carcinoma of the colon or rectum
* Recurrent or progressive after failing prior fluorouracil and irinotecan chemotherapy, sequentially or in combination, unless unable to tolerate irinotecan
* Measurable disease
PATIENT CHARACTERISTICS:
Age:
* 18 to 75
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Granulocyte count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* Hemoglobin at least 10 g/dL
Hepatic:
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* AST and ALT no greater than 5 times ULN
* PT/aPTT no greater than 1.2 times ULN
Renal:
* Creatinine no greater than 1.5 mg/dL
* Creatinine clearance at least 50 mL/min
* No impaired renal function
Cardiovascular:
* No impaired cardiac function
Other:
* No active infection
* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* See Disease Characteristics
* At least 4 weeks since prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* At least 4 weeks since prior radiotherapy
Surgery:
* Not specified
Other:
* No other concurrent anticancer drugs
* No concurrent chronic non-steroidal anti-inflammatory agents
* No concurrent chronic therapeutic anticoagulation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT00021268
Study Brief:
Protocol Section:
NCT00021268